Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $202.75 USD
Change Today +0.87 / 0.43%
Volume 761.1K
SHPG On Other Exchanges
SHPG is not on other exchanges.
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/15 - $270.63
52 Week Low
10/15/14 - $156.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc-adr (SHPG) Key Developments

Shire plc Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:25 AM

Shire plc Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:25 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Jeffrey Poulton, Chief Financial Officer and Director, Philip J. Vickers, Head of Research and Development.

Shire Receives European Approval for INTUNIV® - (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents

Shire announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. INTUNIV must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. The European Commission decision to grant approval is based on data from three pivotal Phase 3 studies investigating the short- and long-term safety and efficacy of INTUNIV in children and adolescents with ADHD. The European Commission decision to grant Marketing Authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in July 2015 and applies to all 28 EU member states and Iceland, Liechtenstein and Norway.

Shire plc Presents at Bank of America Merill Lynch Global Healthcare Conference, Sep-17-2015 06:25 AM

Shire plc Presents at Bank of America Merill Lynch Global Healthcare Conference, Sep-17-2015 06:25 AM. Venue: London, United Kingdom. Speakers: Jeffrey Poulton, Chief Financial Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $202.75 USD +0.87

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.20 AUD +0.25
Eisai Co Ltd ¥6,913 JPY +229.00
Mylan NV $42.67 USD +0.44
Perrigo Co PLC $158.34 USD +2.22
UCB SA €68.13 EUR -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation SHPG Industry Range
Price/Earnings 13.1x
Price/Sales 6.5x
Price/Book 4.4x
Price/Cash Flow 12.5x
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at